ATE235919T1 - Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen - Google Patents

Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen

Info

Publication number
ATE235919T1
ATE235919T1 AT95921031T AT95921031T ATE235919T1 AT E235919 T1 ATE235919 T1 AT E235919T1 AT 95921031 T AT95921031 T AT 95921031T AT 95921031 T AT95921031 T AT 95921031T AT E235919 T1 ATE235919 T1 AT E235919T1
Authority
AT
Austria
Prior art keywords
defrosting
proteins
preventing aggregation
peptides during
during rehydration
Prior art date
Application number
AT95921031T
Other languages
English (en)
Inventor
Bruce Joseph Roser
Camilo Colaco
Jaap Kampinga
Christopher Smith
Original Assignee
Elan Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22958303&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE235919(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Drug Delivery Ltd filed Critical Elan Drug Delivery Ltd
Application granted granted Critical
Publication of ATE235919T1 publication Critical patent/ATE235919T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT95921031T 1994-06-02 1995-06-02 Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen ATE235919T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25296794A 1994-06-02 1994-06-02
PCT/GB1995/001277 WO1995033488A1 (en) 1994-06-02 1995-06-02 Method of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby

Publications (1)

Publication Number Publication Date
ATE235919T1 true ATE235919T1 (de) 2003-04-15

Family

ID=22958303

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95921031T ATE235919T1 (de) 1994-06-02 1995-06-02 Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen

Country Status (10)

Country Link
US (2) US6890512B2 (de)
EP (1) EP0762897B1 (de)
JP (2) JP4142095B2 (de)
CN (1) CN1188171C (de)
AT (1) ATE235919T1 (de)
DE (1) DE69530196T2 (de)
DK (1) DK0762897T3 (de)
ES (1) ES2194911T3 (de)
PT (1) PT762897E (de)
WO (1) WO1995033488A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5621094A (en) * 1990-05-14 1997-04-15 Quadrant Holdings Cambridge Limited Method of preserving agarose gel structure during dehydration by adding a non-reducing glycoside of a straight-chain sugar alcohol
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
WO1995033488A1 (en) * 1994-06-02 1995-12-14 Quadrant Holdings Cambridge Limited Method of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
AU3570495A (en) 1994-09-22 1996-04-09 Quadrant Holdings Cambridge Limited Compositions for use in rehydration and nutrition during athletic exercise and methods of making same
US6964771B1 (en) * 1995-06-07 2005-11-15 Elan Drug Delivery Limited Method for stably incorporating substances within dry, foamed glass matrices
CN102416176A (zh) 1995-07-27 2012-04-18 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5958455A (en) * 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
IL124275A (en) 1997-05-02 2002-03-10 Bio Merieux Vitek Inc A method to produce sequences of nucleic acids
US6558901B1 (en) 1997-05-02 2003-05-06 Biomerieux Vitek Nucleic acid assays
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
EP1154796B1 (de) 1999-02-22 2007-06-20 University of Connecticut Neue albuminfreie faktor viii formulierungen
FR2791895B1 (fr) * 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
BR0212833A (pt) 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
SI1458360T1 (sl) 2001-12-19 2011-08-31 Novartis Ag Pulmonalno dajanje aminoglikozidov
US20050163725A1 (en) * 2002-03-20 2005-07-28 Blizzard Charles D. Method for administration of growth hormone via pulmonary delivery
CA2478327A1 (en) * 2002-03-20 2003-10-02 Advanced Inhalation Research, Inc. Hgh (human growth hormone) formulations for pulmonary administration
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
EP1625387A4 (de) * 2003-05-13 2007-08-08 Minerva Biotechnologies Corp Lagerung und verwendung von kolloiden
CN1870980B (zh) 2003-10-23 2010-06-23 大冢制药株式会社 控释无菌阿立哌唑注射剂和方法
EP1730516A1 (de) * 2004-03-30 2006-12-13 Pfizer Products Incorporated Verfahren und vorrichtung zur bewertung pharmazeutischer zusammensetzungen
EP1933867A1 (de) * 2005-10-04 2008-06-25 Alk-Abello A/S Feste impfstoff-formulierung
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
WO2008118691A2 (en) 2007-03-22 2008-10-02 The Regents Of The University Of Colorado Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
EP2162120B1 (de) * 2007-06-04 2016-05-04 Bend Research, Inc Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
RU2010104042A (ru) * 2007-07-09 2011-08-20 Новартис АГ (CH) Сохранение вторичной структуры пептида
EP2178518A2 (de) * 2007-07-13 2010-04-28 Bend Research, Inc Nanopartikel mit ionisierbaren und schwach wasserlöslichen zellulose-polymeren
HUE036214T2 (hu) 2007-07-31 2018-06-28 Otsuka Pharma Co Ltd Eljárások aripiprazol-szuszpenzió és fagyasztva szárított készítmény elõállítására
US20090081785A1 (en) * 2007-09-24 2009-03-26 Hememics Biotechnologies, Inc. Desiccated Biologics And Methods Of Preparing The Same
US20090090022A1 (en) * 2007-10-09 2009-04-09 Hememics Biotechnologies, Inc. Desiccation Chamber and Methods for Drying Biological Materials
US9233078B2 (en) * 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
JP4563476B2 (ja) 2008-07-09 2010-10-13 パナソニック株式会社 符号化器、復号化器及び符号化方法
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
BRPI0921429B1 (pt) 2008-11-07 2022-07-12 Takeda Pharmaceutical Company Limited Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
US9827205B2 (en) * 2008-12-12 2017-11-28 Mallinckrodt Pharma Ip Trading D.A.C. Dry powder fibrin sealant
TW201105346A (en) * 2009-07-06 2011-02-16 Sanofi Aventis Deutschland Heat-stable and vibration-stable insulin preparations
US9943075B2 (en) 2010-02-17 2018-04-17 Hememics Biotechnologies, Inc. Preservation solutions for biologics and methods related thereto
JP5341059B2 (ja) * 2010-11-09 2013-11-13 株式会社大塚製薬工場 幹細胞懸濁液
JP5722458B2 (ja) 2010-12-09 2015-05-20 アボット ポイント オブ ケア インコーポレイテッド 試料の混合及び分析を容易にするために抗吸着剤を使用する装置及び方法
CA2836273C (en) 2011-05-17 2019-01-15 Soligenix, Inc. Thermostable vaccine compositions and methods of preparing same
EP4088736A1 (de) 2011-10-25 2022-11-16 Prothena Biosciences Limited Humanisierte anti-amyloid-antikörper-formulierungen und verfahren
US20150044251A1 (en) * 2011-12-23 2015-02-12 Novartis Ag Stable compositions for immunising against staphylococcus aureus
JP5432322B2 (ja) * 2012-05-08 2014-03-05 株式会社大塚製薬工場 トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液
US20150335752A1 (en) * 2012-06-25 2015-11-26 Emergent Product Development Gaithersburg Inc. Temperature Stable Vaccine Formulations
EP3086780A4 (de) 2013-12-27 2017-08-09 Emergent Product Development Gaithersburg Inc. Temperaturstabile impfstoffformulierungen
AU2015339886B2 (en) * 2014-09-29 2019-05-09 Cook General Biotechnology Llc Uses of trehalose in cell suspensions
US20170332623A1 (en) * 2016-03-28 2017-11-23 Cook General Biotechnology Llc Viable cell compositions, and methods related to same
CN107373662B (zh) * 2017-07-07 2020-12-22 江西清源汉本生物科技有限公司 速溶金银花提取物及其制备方法
CN107307422B (zh) * 2017-07-07 2018-09-18 许辉良 速溶石斛提取物及其制备方法
CN107373663B (zh) * 2017-07-07 2020-12-25 江西清源汉本生物科技有限公司 速溶菊花提取物及其制备方法
CA3078625C (en) 2017-10-09 2023-01-17 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
US20200325020A1 (en) * 2017-10-25 2020-10-15 Merck Sharp & Dohme Corp. Adjuvanted vaccines
CA3130668A1 (en) 2019-03-14 2020-12-03 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557717A (en) 1968-05-17 1971-01-26 Gen Mills Inc Process for making candy floss
US3619294A (en) 1968-07-15 1971-11-09 Penick & Ford Ltd Method of combining crystalline sugar with impregnating agents and products produced thereby
US3632357A (en) 1969-07-29 1972-01-04 Standard Brands Inc Method of producing hard candy
US3655442A (en) 1969-08-27 1972-04-11 California & Hawaiian Sugar Method of making sugar and sugar products
US4127502A (en) 1977-06-10 1978-11-28 Eastman Kodak Company Stabilizers for reconstituted, lyophilized samples
DE2748132A1 (de) 1977-10-27 1979-05-03 Behringwerke Ag Stabilisator fuer polysaccharid
US4158544A (en) 1978-07-17 1979-06-19 Beckman Instruments, Inc. Process for preparing a biological composition for use as a reference control in diagnostic analysis
US4588744A (en) 1978-09-19 1986-05-13 Mchugh John E Method of forming an aqueous solution of 3-3-Bis(p-hydroxyphenyl)-phthalide
US4327076A (en) 1980-11-17 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4327077A (en) 1981-05-29 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4457916A (en) 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
US4883762A (en) 1983-06-06 1989-11-28 Ciba Corning Diagnostics Corp. Stabilized isoenzyme control products
US4865871A (en) 1983-08-23 1989-09-12 Board Of Regents The University Of Texas System Method for cryopreparing biological tissue
DE3445010A1 (de) 1984-12-10 1986-06-19 Boehringer Mannheim Gmbh Kontroll- bzw. eichserum fuer die lipid-diagnostik
EP0229810B1 (de) 1985-07-09 1991-10-16 Quadrant Bioresources Limited Beschützung von proteinen und ähnlichem
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
US4762857A (en) 1986-05-30 1988-08-09 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
GB8715238D0 (en) * 1987-06-29 1987-08-05 Quadrant Bioresources Ltd Food process
GB8801338D0 (en) 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
CA1331133C (en) 1988-03-01 1994-08-02 Michael Jon Pikal Pharmaceutical growth hormone formulations
US5262296A (en) * 1988-03-30 1993-11-16 Toray Industries, Inc. Freeze-dried composition containing enzyme-labeled anti-human interferon-β antibody and enzyme immunoassay kit containing the composition
US5059518A (en) * 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
US5102788A (en) * 1988-11-21 1992-04-07 Hygeia Sciences, Inc. Immunoassay including lyophilized reactant mixture
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
GB8917470D0 (en) 1989-07-31 1989-09-13 Quadrant Bioresources Ltd Composition and method
AU650678B2 (en) 1990-08-10 1994-06-30 Analytical Control Systems, Inc. Stabilization (using gelatin from a cold water fish) of enzymes in diagnostic controls
US5200399A (en) 1990-09-14 1993-04-06 Boyce Thompson Institute For Plant Research, Inc. Method of protecting biological materials from destructive reactions in the dry state
US5242792A (en) * 1991-02-25 1993-09-07 The United States Of America As Represented By The Secretary Of The Navy Method for the preservation of red blood cells by lyophilization using glycerol or inositol with disaccharides
US5422384A (en) 1992-11-25 1995-06-06 Battelle Memorial Institute Glass/polymer composites and methods of making
EP0717988B1 (de) 1993-08-20 2001-10-17 Nippon Shinyaku Company, Limited Im magen verbleibende zubereitung, quellender formkörper und herstellungsverfahren
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
WO1995033488A1 (en) 1994-06-02 1995-12-14 Quadrant Holdings Cambridge Limited Method of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
EP0831790B1 (de) 1995-06-07 2003-05-07 Elan Drug Delivery Limited Verfahren zur stabilen einarbeitung von substanzen in trockene geschäumte glasmatrizen und auf diese weise hergestellte zusammensetzungen

Also Published As

Publication number Publication date
US20050163750A1 (en) 2005-07-28
DE69530196D1 (de) 2003-05-08
CN1188171C (zh) 2005-02-09
PT762897E (pt) 2003-07-31
US20010055583A1 (en) 2001-12-27
EP0762897A1 (de) 1997-03-19
CN1156967A (zh) 1997-08-13
ES2194911T3 (es) 2003-12-01
DE69530196T2 (de) 2003-11-20
US6890512B2 (en) 2005-05-10
EP0762897B1 (de) 2003-04-02
JP4142095B2 (ja) 2008-08-27
DK0762897T3 (da) 2003-07-21
JPH10500990A (ja) 1998-01-27
WO1995033488A1 (en) 1995-12-14
JP2008179636A (ja) 2008-08-07

Similar Documents

Publication Publication Date Title
ATE235919T1 (de) Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen
ATE159429T1 (de) Methode zum überbringen von agenzien an zielzellen
WO1998020133A3 (en) Proteins with enhanced levels of essential amino acids
DE69535948D1 (de) Von wd-40 abstammende peptide und ihre verwendung
ATE132164T1 (de) Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
DK332684D0 (da) Modificerede protease-inhibitorer samt deres fremstilling og anvendelse
NO990086L (no) Avkortete, l°selige tumornekrosefaktorreseptorer av type I og type II
MX9203519A (es) Metodo de recombinacion para la produccion de inhibidores de proteasa de serina y secuencias de adn utiles para los mismos.
DK0572688T3 (da) Peptider, med organ-beskyttende aktivitet, fremgangsmåde til deres fremstilling og deres anvendelse ved terapi
EP0422125A4 (en) Platelet blocking peptides
DK568287A (da) Relativt lavmolekylaere peptider og deres anvendelse som renininhibitorer
RU94041224A (ru) Пептиды с органозащитной активностью, фармацевтическая композиция на их основе и их применение в терапии
ATE270305T1 (de) Peptide des antisekretorischen faktors, welches krankhafte permeabilitätsanderungen reguliert
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
HUP9900506A2 (hu) Protrombinszármazékok
ATE110742T1 (de) Peptid-verbindungen.
DE69431603D1 (de) Oligopeptide hergeleitet von fragmenten des c-reaktiven proteins
NO892266L (no) Amblyommin, et nytt virkemiddel for antikoagulasjonsterapien.
PE92298A1 (es) Variantes de aprotinina con propiedades mejoradas
DE69433745D1 (de) Modifizierte, verkürzte regulatoren des komplementsystems
DE3880122D1 (de) Verfahren zur solubilisierung von unloeslichem protein.
SE9604439D0 (sv) New receptor
ATE191928T1 (de) Zellzyklus- kontrollzusammensetzungen und methoden diese zu benutzen.
WO1998029436A3 (en) Lebetin peptides as platelet aggregation inhibitors
ATE71844T1 (de) Potenzierung der antihypertensiven wirkung von ace-inhibitoren.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0762897

Country of ref document: EP

EEFA Change of the company name
REN Ceased due to non-payment of the annual fee
RZN Patent revoked